French Company Gets FDA Breakthrough Status For Brain Device
The US FDA has designated Carthera’s SonoCloud-9 as a breakthrough device. The French company’s ultrasound technology is designed to treat a wide range of brain diseases, including recurrent glioblastoma.
You may also be interested in...
CarThera has secured its first financial round from institutional investors to launch a pivotal trial evaluating the company's Sonocloud ultrasound therapy for patients with recurrent glioblastoma.
The US FDA has updated guidance on computer-assisted detection devices that was first released in 2012. The document, which is intended to help developers win FDA approval of their products, was last updated in 2020.
The US FDA has labelled a recall of several hundred components of the LifeSPARC circulatory support system from LivaNova as class I, the agency’s most serious recall designation.